It’s our mission to deliver innovative therapies to improve the lives of patients impacted by cancer and autoimmune diseases.

MorphoSys' mission

MorphoSys mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

15/03/2021
MorphoSys AG Presents Results for Full Year 2020
09/03/2021
Invitation to MorphoSys' Full Year Results 2020 Conference Call on...
02/03/2021
MorphoSys's Licensing Partner GSK Shared Preliminary Results From...
01/03/2021
Ad hoc: MorphoSys AG preliminary results for the fiscal year 2020...
25/01/2021
MorphoSys AG: MorphoSys and I-Mab Announce First Patient Dosed in U.S....
12/01/2021
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug...
11/01/2021
MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference
06/01/2021
MorphoSys Appoints Sung Lee as Chief Financial Officer
05/01/2021
MorphoSys and Incyte Announce the Acceptance of the Swissmedic Marketing...
17/12/2020
MorphoSys AG: Corporate Calendar 2021

March 16, 2021
Conference Call and Webcast
Results Year End 2020

test
Full details